Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy
2019/06/27 by Angela K. Birnbaum, Ashwin Karanam, Susan E. Marino +5 · 30 citations
Medicine · #Cannabis and Cannabinoid Research #Diet, Metabolism, and Disease #Epilepsy research and treatment
paper · doi:10.1111/epi.16093
Abstract
Abstract Objective To evaluate the pharmacokinetics of a purified oral cannabidiol ( CBD ) capsule administered with and without food in adults with refractory epilepsy. Methods Adult patients who were prescribed CBD for seizures, had localization‐related intractable epilepsy with ≥4 seizures per month, and qualified for Minnesota cannabis were enrolled. A single dose of 99% pure CBD capsules was taken under both fasting (no breakfast) and fed (high fat 840‐860 calorie) conditions. Blood sampling for CBD plasma concentrations was performed under each condition between 0 and 72 hours post‐dose and measured by a validated liquid chormatography‐mass spectometry assay. CBD pharmacokinetic profiles including maximum concentration ( C max ), area‐under‐the‐curve from zero to infinity ( AUC 0‐∞ ), and time‐to‐maximum concentration ( T max ) were calculated. The confidence intervals ( CI s) for log‐transformed C max and AUC 0‐∞ ratios between fed and fasting states were calculated. Seizure and adverse events information was collected. Results Eight patients completed the study. On average C max was 14 times and AUC 0‐∞ 4 times higher in the fed state. The 90% CI for the ratio of fed versus fast conditions for C max and AUC 0‐∞ were 7.47‐31.86 and 3.42‐7.82, respectively. No sequence or period effect for C max and AUC 0‐∞ was observed. No adverse events were reported. Significance Administering CBD as a capsule rather than a liquid allows for more precise determination of pharmacokinetics parameters and is more representative of CBD swallowed products. The fat content of a meal can lead to significant increases in C max and AUC 0‐∞ and can account for variability in bioavailability and overall drug exposure within patients with oral products.
Cited by
- Pharmacokinetic variability and use of therapeutic drug monitoring of cannabidiol in patients with refractory epilepsy
- Population pharmacokinetics of cannabidiol and the impact of food and formulation on systemic exposure in children with drug‐resistant developmental and epileptic encephalopathies
- Effects of Simulated Exogenous and Endogenous Lipid Microenvironments on Cannabidiol Disposition and Cytochrome P450 2C19-Mediated Drug Interactions: New Mechanistic Insights
- Does the “Entourage Effect” in Cannabinoids Exist? A Narrative Scoping Review
- Pharmacokinetics of escalating single‐dose administration of cannabidiol to cats
- Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. [europepmc]
- The nephrologist's guide to cannabis and cannabinoids. [europepmc]
- Is cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy? [europepmc]
- A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers. [europepmc]
- Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research. [europepmc]
- Towards Better Delivery of Cannabidiol (CBD). [europepmc]
- Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract. [europepmc]
- Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. [europepmc]
- Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps. [europepmc]
- Cannabidiol: pharmacology and therapeutic targets. [europepmc]
- Cannabidiol in epilepsy: The indications and beyond. [europepmc]
- Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies. [europepmc]
- Cannabis, Cannabidiol Oils and Tetrahydrocannabinol-What Do Veterinarians Need to Know? [europepmc]
- Cannabidiol (CBD) Use by Older Adults for Acute and Chronic Pain. [europepmc]
- Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study. [europepmc]
- Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. [europepmc]
- Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products. [europepmc]
- Statement on safety of cannabidiol as a novel food: data gaps and uncertainties. [europepmc]
- Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation. [europepmc]
- Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. [europepmc]
- Effects of Oral Cannabinoids on Systemic Inflammation and Viral Reservoir Markers in People with HIV on Antiretroviral Therapy: Results of the CTN PT028 Pilot Clinical Trial. [europepmc]
- Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial. [europepmc]
- Cannabidiol and brain function: current knowledge and future perspectives. [europepmc]
- CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions. [europepmc]
- Metabolism and liver toxicity of cannabidiol. [europepmc]
Related